| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥0.3B | ¥1.1B | -71.3% |
| Operating Income | ¥-5.2B | ¥-6.0B | +13.5% |
| Ordinary Income | ¥-5.3B | ¥-6.4B | +16.2% |
| Net Income | ¥-3.2B | ¥-7.5B | +57.8% |
| ROE | -313.8% | -119.3% | - |
FY2026 Q3 cumulative results: Revenue 0.3B yen (YoY -71.3%), Operating Income -5.2B yen (operating loss improved +13.5% from prior year loss of -6.0B yen), Ordinary Income -5.3B yen (loss improved +16.2% from -6.4B yen), Net Income -3.2B yen (loss improved +57.8% from -7.5B yen). The company achieved significant improvement in all profit metrics despite revenue contraction, reflecting operating leverage effects from business restructuring. Total assets decreased sharply to 7.3B yen from 35.4B yen, primarily due to disposal of real estate assets as part of strategic shift to Medical business segment. The business operates in a loss-making phase with negative gross margin of -0.2%, indicating revenue insufficient to cover cost of sales, while SG&A expenses of 5.2B yen remain structurally elevated. Full-year guidance projects revenue of 10.6B yen (implying substantial Q4 recovery) and net income of 0.7B yen (turning positive). Financial leverage remains elevated at D/E ratio of 6.19x with interest-bearing debt of 26.9B yen against equity of 1.0B yen.
Revenue declined 71.3% YoY to 0.3B yen, driven by the strategic exit from Real Asset business segment through disposal of property holdings completed in Q1 (May 2025). The company transitioned from a dual-segment structure (Medical and Real Asset) to a single Medical business segment, resulting in temporary revenue contraction during the transition period. Cost of sales was 0.3B yen, generating negative gross margin of -0.2%, indicating pricing or inventory valuation issues during the business model transition. The company incurred SG&A expenses of 5.2B yen (SG&A ratio of 1579.0% against revenue), representing fixed cost burden unabsorbed by the reduced revenue base. This structural cost base contributed to operating loss of -5.2B yen, though the loss narrowed by 0.8B yen from prior year's -6.0B yen, reflecting incremental cost reduction efforts. Non-operating expenses totaled 0.2B yen, primarily interest expense of 0.2B yen on the substantial debt portfolio, creating minimal gap between operating income (-5.2B yen) and ordinary income (-5.3B yen). Extraordinary items had material impact: extraordinary income of 2.1B yen and extraordinary loss of 1.3B yen (including impairment loss of 0.7B yen and loss on asset disposal of 0.5B yen), resulting in net extraordinary gain of 0.8B yen. These non-recurring items relate to the real estate asset disposal program. The combination of narrowed operating loss and net extraordinary gain resulted in net income loss of -3.2B yen, improving 4.4B yen from prior year's -7.5B yen. This represents a revenue down/profit improved pattern, where operating leverage from fixed cost base and one-time gains from restructuring drove bottom-line improvement despite top-line contraction.
[Profitability] ROE of -313.8% reflects the loss-making operations against diminished equity base of 1.0B yen, deteriorating from prior year due to cumulative deficit accumulation. Operating margin of -1578.8% indicates severe structural unprofitability with SG&A expenses exceeding revenue by over 15-fold. Net profit margin of -960.6% incorporates both operational losses and impact of restructuring-related extraordinary items. Gross margin of -0.2% signals fundamental business model challenges in the Medical segment's current configuration. [Cash Quality] Cash and deposits of 2.5B yen provide 0.62x coverage of short-term debt of 4.0B yen, indicating constrained liquidity. Short-term debt increased 33.3% from 3.0B yen to 4.0B yen YoY, elevating near-term refinancing pressure. [Investment Efficiency] Asset turnover of 0.045x (revenue of 0.3B yen against total assets of 7.3B yen) reflects the transitional state with revenue generation not yet aligned to the restructured asset base. [Financial Health] Equity ratio of 13.9% (equity of 1.0B yen against total assets of 7.3B yen) indicates thin capitalization. Current ratio of 136.0% appears adequate on surface but masks the cash-to-short-term-debt coverage constraint of 0.62x. Debt-to-equity ratio of 6.19x substantially exceeds prudent leverage levels, with interest-bearing debt of 26.9B yen (including long-term loans of 22.9B yen) overwhelming the equity base. Retained earnings deficit of -29.4B yen expanded 2.1B yen YoY, eroding net worth. Interest expense of 0.2B yen against operating income of -5.2B yen results in negative interest coverage.
Cash and deposits decreased to 2.5B yen from prior period levels, reflecting the combined effects of operating losses and debt servicing obligations. The business consumed cash in operations given negative operating income of -5.2B yen, offset partially by working capital movements including reduction of property, plant and equipment from 29.6B yen to 0.2B yen (decline of 29.4B yen), representing proceeds from real estate asset disposals. This asset monetization provided extraordinary income of 2.1B yen while incurring disposal losses of 1.3B yen, generating net cash inflow that partially offset operating cash burn. Trade receivables increased 0.05B yen to 0.07B yen despite revenue contraction, suggesting collection timing factors. Inventories of 0.5B yen remain relatively unchanged, representing slow-moving stock given the revenue base. Short-term borrowings increased 1.0B yen to 4.0B yen, indicating financing cash inflow to supplement liquidity. The cash-to-short-term-debt coverage of 0.62x signals that liquid assets are insufficient to fully cover near-term debt obligations without additional asset sales or refinancing. Current liabilities of 5.1B yen are covered 1.36x by current assets of 6.9B yen, but this includes slower-moving items beyond cash. The financing structure with long-term loans of 22.9B yen provides extended maturity profile, though servicing this debt load requires sustained operating improvement.
Ordinary income of -5.3B yen versus operating income of -5.2B yen shows minimal non-operating net contribution of approximately -0.1B yen, consisting primarily of interest expense of 0.2B yen against negligible non-operating income of 0.1B yen. Non-operating items represent 67% of revenue (0.2B yen expense against 0.3B yen revenue), reflecting the outsized interest burden relative to the current revenue scale. The more significant earnings quality consideration relates to extraordinary items totaling net positive 0.8B yen (extraordinary income 2.1B yen minus extraordinary loss 1.3B yen), comprising non-recurring gains from real estate asset disposals offset by associated impairment losses and disposal costs. These extraordinary items contributed meaningfully to net income improvement from -7.5B yen to -3.2B yen, indicating approximately 45% of the year-over-year profit improvement derives from non-recurring restructuring activities rather than operational improvement. Comprehensive income of -3.2B yen matches net income with negligible other comprehensive income components, confirming the reported loss fully flows through to comprehensive results. The absence of operating cash flow data in quarterly reporting limits direct assessment of cash earnings quality, though the negative operating margin of -1578.8% and continued operating losses indicate earnings remain non-cash-generative from core operations. The business model transition to Medical segment following Real Asset disposal is ongoing, with Q3 results reflecting transitional costs and reduced revenue during establishment of new operational foundation.
Full-year guidance projects revenue of 10.6B yen against Q3 cumulative actual of 0.3B yen, representing 2.8% progress rate. This implies Q4 revenue requirement of approximately 10.3B yen to achieve guidance, indicating either substantial business acceleration, contracted revenue with long collection cycles, or anticipated recognition of deferred revenue. Operating income guidance of -1.2B yen compares to Q3 cumulative operating loss of -5.2B yen, implying Q4 operating income requirement of approximately +4.0B yen to meet guidance. Ordinary income guidance of -1.4B yen versus Q3 cumulative of -5.3B yen similarly requires Q4 improvement of approximately +3.9B yen. Net income guidance of 0.7B yen (positive) versus Q3 cumulative loss of -3.2B yen requires Q4 net income of approximately +3.9B yen. The substantial gap between Q3 progress rates (revenue 2.8%, operating income 433% of full-year loss) and full-year targets suggests guidance assumes material Q4 developments such as significant Medical segment contract deliveries, additional extraordinary gains from asset management activities, or other non-linear revenue recognition patterns. No guidance revision was announced this quarter. The progress rate deviation of approximately 47 percentage points below standard Q3 expectation of 75% for revenue indicates either back-end loaded revenue profile or execution risk to stated guidance. Given the business model transition from Real Asset to Medical segment and the Q1 timing of final real estate disposal, guidance likely contemplates Medical business scale-up in latter fiscal periods.
Liquidity and refinancing risk represents the primary concern, with cash coverage of short-term debt at 0.62x (2.5B yen cash against 4.0B yen short-term borrowings) and short-term debt increasing 33.3% YoY, creating dependency on continued credit facility access or additional asset monetization to meet near-term obligations. Structural unprofitability in current Medical business configuration poses execution risk, with operating margin of -1578.8% and SG&A of 5.2B yen unabsorbed by revenue of 0.3B yen, requiring either rapid revenue scale-up or significant cost restructuring to achieve sustainable profitability. Debt service burden and capital structure sustainability concerns arise from debt-to-equity ratio of 6.19x with total interest-bearing debt of 26.9B yen against equity of 1.0B yen, while cumulative retained earnings deficit of -29.4B yen constrains financial flexibility and creates potential covenant pressure if losses continue.
[Industry Position] (Reference - Proprietary Analysis) The company operates significantly below IT and Telecom industry standards across all financial metrics. Profitability: Operating margin of -1578.8% compares unfavorably to industry median of 8.2% (2025-Q3, n=104 companies), placing the company in structural loss position versus profitable peer group. ROE of -313.8% versus industry median of 8.3% reflects loss-making operations and weak capitalization. Net profit margin of -960.6% substantially trails industry median of 6.0%. Financial Health: Equity ratio of 13.9% falls well below industry median of 59.2%, indicating materially weaker balance sheet capitalization. Current ratio of 1.36x lags industry median of 2.15x, though remains above 1.0x threshold. The company's debt-to-equity configuration substantially exceeds typical industry leverage patterns. Efficiency: Asset turnover of 0.045x significantly trails industry median of 0.67x, reflecting the transitional business state with revenue generation not yet established relative to asset base. Growth: Revenue growth of -71.3% YoY diverges dramatically from industry median growth of 10.4%, reflecting the strategic business model transition from Real Asset to Medical segment. These metrics position the company in turnaround/restructuring phase rather than steady-state operations, with performance gaps indicating substantial operational improvement requirements to achieve industry-standard financial profile. (Industry: IT and Telecom, Comparison: 2025-Q3 period, Source: Proprietary analysis)
The company demonstrates clear evidence of strategic business transformation from Real Asset to Medical segment, with Q1 completion of real estate portfolio disposal reducing total assets from 35.4B yen to 7.3B yen and transitioning to single-segment Medical business operations. Bottom-line improvement of 57.8% in net income (from -7.5B yen to -3.2B yen loss) while revenue declined 71.3% indicates successful extraction of value from legacy Real Asset portfolio through extraordinary gains of 2.1B yen, partially validating the restructuring strategy. However, core Medical business profitability remains unestablished with negative gross margin of -0.2% and operating loss of -5.2B yen against 0.3B yen revenue, creating substantial execution risk regarding whether the Medical segment can achieve sufficient scale and margins to absorb the 5.2B yen fixed cost base. The financial structure presents material refinancing risk with debt-to-equity of 6.19x, cash coverage of short-term debt at only 0.62x, and short-term borrowings increasing 33.3% to 4.0B yen, necessitating either sustained credit facility support, additional asset monetization, or equity infusion to maintain operations through the transition period. Full-year guidance implying 10.3B yen Q4 revenue requirement versus 0.3B yen Q3 cumulative suggests either substantial contracted backlog with fourth-quarter delivery timing or potential guidance revision risk.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.